Larimar Therapeutics Announces Conference Call on the Nomlabofusp Program for the Treatment of Friedreich's Ataxia

Core Insights - Larimar Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, with its lead compound nomlabofusp targeting Friedreich's ataxia [3]. Group 1: Company Overview - Larimar Therapeutics is listed on Nasdaq under the ticker LRMR and is dedicated to addressing complex rare diseases [3]. - The company is developing nomlabofusp as a potential treatment for Friedreich's ataxia and plans to utilize its intracellular delivery platform for designing other fusion proteins targeting additional rare diseases [3]. Group 2: Upcoming Events - Larimar will host a conference call and webcast on September 29, 2025, at 8:00 am EDT to discuss updates on the nomlabofusp clinical development program, including data from an ongoing long-term open label study [1][2].